Shares of the restaurant chain began trading at HK$7.19 per share, unchanged from the offer price, before plunging 7 per cent ...

Jiangsu Hengrui Pharmaceuticals, a leading Chinese developer of novel drugs that recently received approval to go public in ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is aiming to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a regulatory filing made on Thursday.

Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO ...

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

This digital payment services provider is likely to get a lift from China's initiatives to boost domestic consumption.

China’s Zijin Mining Group (OTCPK:ZIJMF) (OTCPK:ZIJMY) has picked Citic Securities Co. and Morgan Stanley (MS) to lead the ...

Chinese battery giant Contemporary Amperex Technology is planning to raise as much as US$4.0 billion in the year’s biggest ...

The China-based casual dining brand began trading its IPO after pricing its 168,364,000 shares at HKD 7.19 per share.

SINGAPORE] Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as ...

Xpeng Inc. is considering an initial public offering for its flying car unit, Xpeng Aeroht, according to people familiar with ...